Con: Asymptomatic Ulcerative Colitis Patients on an Immunomodulator with Persistent Moderate Mucosal Inflammation Should Not Add A Biologic or Switch to.

Slides:



Advertisements
Similar presentations
Indeterminate colitis Karel Geboes. Case History Male patient, ° : Hyperthyroidism 1996 : PSC 2003 : Ulcerative colitis –2006 : surveillance.
Advertisements

IV Cyclosporin Vs IV Steroids as Single Therapy for Severe Attacks of UC Gastroenterology 2001;120: Matt Johnson and Dr. M. Smith.
Crohns Disease: Managing and Monitoring Mucosal Healing in the Small Bowel
Who should receive early anti-TNF therapy: With what benefits and risks? Ted Denson, MD Cincinnati Childrens Hospital Medical Center University of Cincinnati.
University Colorado Denver Center for Human Simulation
Methotrexate Indications and Approaches
Monotherapy using 6-MP or azathioprine for Crohn’s disease is dead: out with the old and in with the new Stephen B. Hanauer, MD Professor of Medicine Clinical.
Miguel Regueiro, M.D. Professor of Medicine
Immunomodulators and Biologics Maria T. Abreu, MD University of Miami Miller School of Medicine Miami, Florida.
Journal Club: Biologic Agents in UC, Systematic Review and Network Meta-analysis, by Danese et al., Annals 2014 Barrett G. Levesque, MD Assistant Professor.
Cure’s GTX Licensing Opportunity
Thomas Ullman, M.D. Chief Medical Officer
Colitis in the Very Young
Dr Mohammad Sadrkabir. The American Journal of GASTROENTEROLOGY 2011.
Challenges in Surgery for Severe, Refractory Ulcerative Colitis: Case Studies Phillip R. Fleshner,M.D. Shierley,Jesslyne,and Emmeline Widjaja Chair in.
Thiopurines still have a role in the management of pediatric IBD Athos Bousvaros MD, MPH Associate Director, IBD program Boston Children’s Hospital.
Emerging treatments in Crohn’s disease and ulcerative colitis
Treating the Outpatient with Severe IBD: Case Discussions William Tremaine, MD Corey A. Siegel, MD.
End points in IBD treatment Mucosal healing Vs Symptom relief Jose Francis Lakeshore Hospital Kochi.
Treating the outpatient with severe IBD: Case studies Daniel H. Present, MD, MACG Clinical Professor of Medicine The Mount Sinai School of Medicine Russell.
How Should We be Assessing and Documenting Endoscopies in IBD: Incorporating Standard Scoring Systems into Patient Care Gary R Lichtenstein, MD Director,
The Patient With Pyoderma Gangrenosum Maria T. Abreu, MD Chief, Division of Gastroenterology University of Miami Miller School of Medicine Miami, Florida.
Ghassan Wahbeh MD Associate Professor, Director IBD Program Seattle Children’s Hospital University of Washington.
GTX: An Opportunity Not to be Missed? Team Veritas Reuben Estrada MBA Candidate Fang Fang PhD Candidate Stan Guthrie PhD Candidate Minlee Kim PhD Candidate.
When can we use combination therapy for our pediatric IBD patients? Athos Bousvaros MD, MPH Advances in IBD Dec 2014.
Prevention of Postoperative Crohn’s disease
Joel R. Rosh, MD Director, Pediatric Gastroenterology
Asymptomatic UC patients on an immunomodulator with persistent moderate mucosal inflammation should either add a biologic or switch to a biologic William.
An interesting case of a 42 year old woman with diarrhea Christie Seibert, MD July 28, 2004.
Inflammatory Bowel Disease Treatment. Epidemiology Clinical Laboratory Imaging Pathology Response to treatment IBD.
Case Study Advances 2014 Betty White C-NP
Medical Management of Ulcerative Colitis Conrad Beckett Bradford Royal Infirmary M62 Course March 2006.
William J. Sandborn, MD Chief, Division of Gastroenterology
“Antibiotics and corticosteroids: Indications and approaches”
The association between endoscopic and histological inflammation in ulcerative colitis Klaus Theede, MD Gastrounit, Medical Division Copenhagen University.
Fecal calprotectin DR Amin Eftekhari.
1 Top-Down vs Step-Up Trial Endoscopic Substudy: Mucosal Healing Patients, % P
The only end-points of therapy that matter are mucosal healing, normal blood work, and negative radiologic studies. Robert N. Baldassano, MD Colman Family.
It's Time A 63-year-old woman was admitted because of severe abdominal pain, fatigue and bloody diarrhea.
IBD Cases Stephen B. Hanauer, MD Professor of Medicine Feinberg School of Medicine Medical Director, Digestive Health Center.
You Can Never Stop a Biologic
STUDY 303 A Phase III, Randomized, Multi-Center, Open-Label, 12 to 14 Month Extension Study to Evaluate the Safety and Tolerability of Mesalamine Given.
Should we change how we position biologics in ulcerative colitis? Bruce E. Sands, MD, MS Chief of the Dr. Henry D. Janowitz Division of Gastroenterology.
Time to initial resolution of rectal bleeding and high stool frequency in patients who achieved clinical and endoscopic remission after up to 8 weeks.
GI tract infections in IBD: Detection and treatment of Clostridium difficile, CMV and enteric pathogens: Case studies David G. Binion, MD Bruce E. Sands,
Mucosal Healing Predicts Late Outcomes After the First Course of Corticosteroids for Newly Diagnosed Ulcerative Colitis SANDRO ARDIZZONE,* ANDREA CASSINOTTI,*
Xavier Roblin, MD, PhD 1, M. Rinaudo, MD 2, E. Del Tedesco, MD 1, J.M. Phelip, MD, PhD 1, C. Genin, MD, PhD 2, L. Peyrin-Biroulet, MD, PhD 3 and S. Paul,
GASTROENTEROLOGY 2008; 134 :688–695 소화기내과 R4 이 재 연.
N Engl J Med 2012;367: Dae youn.kim/Prof.Chang hyun Lee.
Cumulative Probability of Developing Colon Cancer in UC Patients
Ulcerative colitis (UC)
Goals of Therapy for Patients With UC
Optimizing Use of Biological Agents in Ulcerative Colitis
Complicated Cases in Ulcerative Colitis
Pathways in Managing Ulcerative Colitis
The Probiotic Preparation, VSL#3 Induces Remission in Patients With Mild-to- Moderately Active Ulcerative Colitis  Ajit Sood, Vandana Midha, Govind K.
Managing IBD.
Raymond Cross, MD, MS, AGAF Associate Professor of Medicine
Illustrations in Ulcerative Colitis
The emerging role of histologic disease activity assessment in ulcerative colitis  Rish K. Pai, MD, PhD, Vipul Jairath, MD, PhD, Niels Vande Casteele,
Volume 384, Issue 9940, Pages (July 2014)
Optimizing Outcomes in Crohn Disease
Methotrexate for Ulcerative Colitis: To Use or Not to Use?
Volume 384, Issue 9940, Pages (July 2014)
Microscopic Colitis Gastroenterology
Phase III randomized controlled trial to compare biosimilar infliximab (CT-P13) with innovator infliximab in patients with active Crohn’s disease: 1-year.
Presentation data from US VICTORY Consortium
Presentation data from US VICTORY Consortium
Crohn’s Disease Biologic Pathway
Endoscopic picture of ulcerative colitis with (A) Mayo grade 3 score with friable mucosa and large ulcers. Endoscopic picture of ulcerative colitis with.
Presentation transcript:

Con: Asymptomatic Ulcerative Colitis Patients on an Immunomodulator with Persistent Moderate Mucosal Inflammation Should Not Add A Biologic or Switch to a Biologic William Tremaine, MD

Disclosure Companies have licensed the Mayo Score for UC and I have received $12,000 personal compensation from Mayo Clinic’s royalty sharing policy.

Regarding Disclosures: Editorial Comments 2009 Nominee Unpaid Taxes Outcome Tim Geithner $34,000 $34,000Confirmed Tom Daschle $128,000Withdrew Dollar amounts matter

Case History 32 year-old UC for 16 years Steroid responsive Maintenance mesalamine 1.2g/d mercaptopurine 1.5 mg/kg Asymptomatic Surveillance colonoscopy Moderate activity Some normal areas

Case Continued Colon biopsies Patchy minimally active chronic colitis, some areas of inactive colitis, some normal biopsies. No dysplasia CrP = 9.0 normal < 8.0

Case: Management Options 1.Status quo 2.Check 6-TGN, 6 MMP levels Adjust 6-mercaptopurine dose 3.Add an anti-TNFα

Case: Management Options 1.Status quo 2.Check 6-TGN, 6 MMP levels Adjust 6-mercaptopurine dose 3.Add an anti-TNFα

Alternative Title: Mucosal Healing May be Like a Fedora

Mucosal Healing Fedora FDA Marketers Popular withHipsters Movie Stars NoEasy to SpotYes NoReally Important No Mucosal Healing May be Like a Fedora

Don’t Make Clinical Decisions Based on Mucosal Healing Because: The definition of mucosal healing is fuzzy Treatment based on mucosal healing can be unnecessary and harmful In the long run, mucosal healing isn’t worth much Histologic remission is what’s important Ultimately, population-based studies not treatment trials will prove what is important

What is Mucosal Healing in UC? Mayo UC Score of 0 or 1

Mayo Score: Ulcerative Colitis Stool Frequency0-3 Rectal Bleeding0-3 Endoscopy0-3 Physician’s Global Assessment0-3 Schroeder KW Tremaine WJ NEJM 1987

Mayo Score: Endoscopy Score Normal mucosa0 Mild erythema, mild friability1 Marked erythema, friability erosions2 Spontaneous bleedings, ulcers3 Schroeder KW Tremaine WJ NEJM 1987

Mayo Score: Dec 2, 2013

Don’t Make Clinical Decisions Based on Mucosal Healing Because: The definition of mucosal healing is fuzzy Treatment based on mucosal healing can be unnecessary and harmful In the long run, mucosal healing isn’t worth much Histologic remission is what’s important Ultimately, population-based studies not treatment trials will prove what is important

A Mayo Score of 1 is not as good as a Mayo Score of 0

Fuzzy Math 0 0

Mucosal Healing with Infliximab (IFX): Long-term outcome in UC ACT-1 & ACT IFX 244 Placebo Mayo score: 0,1,2,3 8 wk Conclusion: Mucosal healing at 8wk correlates with improved clinical outcome Colombel JF Gastroenterology 2011;141: % Symptomatic Remission P< Mayo Score

Don’t Make Clinical Decisions Based on Mucosal Healing Because: The definition of mucosal healing is fuzzy Treatment based on mucosal healing can be unnecessary and harmful In the long run, mucosal healing isn’t worth much Histologic remission is what’s important Ultimately, population-based studies not treatment trials will prove what is important

Overtreatment Based on Mucosal Healing: Number Needed to Harm 2 Multicenter German studies Mesalazine vs Placebo for UC 1027 patients Remission Symptomatic Endoscopic Histologic Post hoc analysis Wolff S et al. Inflam Bowel Dis 2013;19:

Overtreatment Based on Mucosal Healing: Number Needed to Harm Endoscopic mucosal disease activity False positive 13.7% NNH = 1 / = 7.3 For asymptomatic UC patients without mucosal healing, additional treatment isn’t needed in about one out of 7 patients. Wolff S et al. Inflam Bowel Dis 2013;19:

Don’t Make Clinical Decisions Based on Mucosal Healing Because: The definition of mucosal healing is fuzzy Treatment based on mucosal healing can be unnecessary and harmful In the long run, mucosal healing isn’t worth much Histologic remission is what’s important Ultimately, population-based studies not treatment trials will prove what is important

1 Yr Mucosal Healing: 5 YR Follow-up IBSEN 354 UC pt Colonoscopy 1 yr & 5 yr after diagnosis Results Predictors of healing at 1 year > 12 yr education Extensive disease % Frøslie E, et al Gastroenterology 2007; 133: P=0.02

Colectomy in UC: Reasons Medically refractory disease Fear of cancer Adverse effects from medical therapy Physician recommendation Unable to afford medical therapy

Colectomy in UC: Reasons Medically refractory disease Fear of cancer Adverse effects from medical therapy Physician recommendation Unable to afford medications ?

1 Yr Mucosal Healing: 5 YR Follow-up Frøslie E, et al Gastroenterology 2007; 133: NS % IBSEN 354 pt at 5 yr

Don’t Make Clinical Decisions Based on Mucosal Healing Because: The definition of mucosal healing is fuzzy Treatment based on mucosal healing can be unnecessary and harmful In the long run, mucosal healing isn’t worth much Histologic remission is what’s important Ultimately, population-based studies not treatment trials will prove what is important

Histologic Remission is Better Than Endoscopic Remission 82 adult UC pts Endoscopy Normal, or erythema Acute histologic activity Acute inflam cells Crypt abscesses Mucin depletion Relapse rate at 12 mo P<0.005 P<0.02 Relapse Rate at 12 Months % Riley SA et al Gut 1991; 32:

Mayo Score vs Histology Beth Israel, Boston 103 pt, UC surveillance 708 colonic segments Mayo Score Biopsies Geboes Score >3.1 Moderate inflam % Rosenberg L et al Clin Gastro Hep 2013; 11:991-6

Abnormal Histology is Like a Positive CrP Mesalazine trials 380 pt with active UC Clinical Activity Index Endoscopy Score Outcome: Higher remission rate if no histologic inflammation before treatment Wolff S et al. Inflam Bowel Dis 2013;19: % Pre-treatment:

Histology is a better measure of remission than white light endoscopy But hi-tech endoscopy may be just as good as histology

Laser Endomicroscopy for Prediction of Relapse in UC Padova, Italy 19 UC pt, 19 Controls Remission Clinical Mayo Endos Score I.V. Fluorescein Confocal probe Fluorescence Crypt Diameter 12 months Clinical Remission % Buda A et al ScienceDirect 4 Sept 2013 Inflammatory Activity

Endoscopic mucosal healing without histologic healing may not protect from cancer

Ulcerative Colitis: Mucosal inflammation is a risk factor for Colorectal Neoplasia Mt Sinai, NYC 408 pt Endoscopic surveillance with biopsies Histologic inflammation graded Mean Histology Inflammation Score HR=2.8 (95% CI = Bansal R Gastroenterology 2007; 133:

Don’t Make Clinical Decisions Based on Mucosal Healing Because: The definition of mucosal healing is fuzzy Treatment based on mucosal healing can be unnecessary and harmful In the long run, mucosal healing isn’t worth much Histologic remission is what’s important Ultimately, population-based studies not treatment trials will prove what is important

Babies Born on 3 Consecutive Nights Wednesday Thursday Friday Are these sequences equally likely?

Babies Born on 3 Consecutive Nights Wednesday Thursday Friday The Law of Small Numbers Kahneman D Thinking Fast and Slow 2011: 115

M M M M M M M M M M M M

Litmus Test for a Disease Modifying Agent Does mucosal healing change the natural history of ulcerative colitis?

Colectomy Rates in Ulcerative Colitis Pre-Biologic EraAnti-TNFα Era Population-based CohortsClinical trials + Referral Center Studies + Population-based Cohorts 29%10-36% Filippi J et al Current Drug Targets 2011; 12:1440-7

Case: Management Options 1.Status quo 2.Add an anti-TNFα Shared Decision Making

Conclusions Mucosal healing is an imperfect endpoint convenient for clinical trials and marketing Histologic healing may be more important Population-based studies, not treatment trials, will ultimately determine best management endpoints